Liquidia Technologies
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Liquidia Technologies sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Liquidia Technologies: 6 sponsored US clinical trials, 1 recruiting.
Liquidia Technologies sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 4 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary Pulmonary Hypertension, with 1 trials.
Upper-quartile sponsor footprint
Liquidia Technologies sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
NCT06129240
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
NCT04691154
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
NCT03992755
Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
NCT03399604
A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001
NCT01224262
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 4 |
Where Liquidia Technologies enrollment is open (later-stage tilt)
1 recruiting of 6 indexed (17% open); 2 completed (33%).
Phase mix: 4 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Primary Pulmonary Hypertension (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Liquidia Technologies: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Liquidia Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Liquidia Technologies page
6 registered trials is a research-attention snapshot, not an endorsement of Liquidia Technologies or any single study.
- 1 of Liquidia Technologies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Primary Pulmonary Hypertension is the condition Liquidia Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Pulmonary Hypertension trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Liquidia Technologies pipeline card: 6 registered trials from official public datasets.Report a data error.